📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
LYKALABS: NCLT reserves order on Scheme of Amalgamation
Lyka Labs Limited announced that the Hon’ble National Company Law Tribunal (NCLT), Ahmedabad Bench, has reserved its order regarding the Scheme of Amalgamation. This follows an earlier update on November 8th, 2025, and a last opportunity granted to the Income Tax counsel to file a reply. The Income Tax Department's counsel has stated no objection to the merger application. The company received a copy of the NCLT order on December 5th, 2025.
Key Highlights
NCLT Ahmedabad Bench reserved its order on the Scheme of Amalgamation.
Income Tax Department's counsel has no objection to the merger application.
Company received NCLT order copy on December 5th, 2025.
💼 Action for Investors
Investors should monitor further announcements from the company regarding the NCLT order. Review the company's website for more information on the amalgamation scheme.
BPL Limited: Supreme Court dismisses SLP (Civil) Diary No. 32849-32850/2025
BPL Limited announced that the Hon'ble Supreme Court of India dismissed a Special Leave Petition (SLP) (Civil) Diary No. 32849-32850/2025 on December 4, 2025. This relates to a payment to an unsecured creditor based on a High Court of Delhi order. The company acknowledges that this sudden outflow of funds will impact the company's cashflows and future expansion projects. Management states they are making efforts to minimize the impact on current operations.
Key Highlights
Hon'ble Supreme Court dismissed SLP (Civil) diary No. 32849-32850/2025
Order passed on 4th December 2025 by Supreme Court
Payment related to an order obtained by an Unsecured creditor from the division bench of the High Court of Delhi
Impact on cashflows of the company and future expansion projects
💼 Action for Investors
Investors should monitor BPL Limited's cash flow situation and future announcements regarding the impact of this legal outcome on the company's financial position and expansion plans. Be aware of potential short-term negative impacts on the stock.
IOLCP gets EDQM CEP Certificate for MINOXIDIL
IOL Chemicals and Pharmaceuticals Limited has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Health Care (EDQM) for its API product "MINOXIDIL" on December 4th, 2025. Minoxidil is used for treating hereditary hair loss. This certification indicates that IOLCP's Minoxidil meets European quality standards, potentially opening up new markets and increasing export opportunities. This regulatory approval can positively impact the company's revenue from API sales.
Key Highlights
EDQM granted CEP Certificate for MINOXIDIL on December 4th, 2025
MINOXIDIL is used as a topical treatment for hereditary hair loss
Certificate issued by the European Directorate for the Quality of Medicines & Health Care (EDQM)
💼 Action for Investors
Investors should monitor IOLCP's sales and revenue growth in the coming quarters to assess the financial impact of this certification. Keep an eye on further regulatory approvals in other geographies.
CEAT to issue NCDs up to ₹250 cr, invests ₹2.07 cr in Indonesia subsidiary
CEAT Limited's board has approved the issuance of unsecured Non-Convertible Debentures (NCDs) for up to ₹250 crores via private placement, in addition to the existing ₹150 crores NCDs. The company will also invest up to IDR 3,800 million (approximately ₹2.07 Crores) in PT CEAT Tyres Indonesia, its subsidiary, through equity share subscription. The NCDs are proposed to be listed on the Wholesale Debt Market Segment of NSE. The investment in the Indonesian subsidiary will increase CEAT's shareholding to approximately 99.93%.
Key Highlights
Issuance of unsecured NCDs up to ₹250 crores.
Investment up to IDR 3,800 Million (₹2.07 Crores approximately) in PT CEAT Tyres Indonesia.
NCD tenure not exceeding 5 years.
Company’s shareholding in PT CEAT Tyres Indonesia shall be about 99.93% after investment.
💼 Action for Investors
Investors should monitor the terms of the NCD issuance and the performance of the Indonesian subsidiary. The NCD issuance could increase debt levels, while the investment in the subsidiary signals a commitment to international expansion.
Shriram Pistons to acquire Grupo Antolin India for ₹16,700 Million
Shriram Pistons & Rings (SPRL) will acquire 100% stake in Antolin Group's Indian operations for approximately ₹16,700 Million. This acquisition includes Antolin Lighting India Private Limited (ALIPL), Grupo Antolin India Private Limited (GAIPL), and Grupo Antolin Chakan Private Limited (GACPL). The target companies have annual revenues of approximately ₹11,791 Million and serve major OEMs across India. The transaction is expected to be completed by January 2, 2026, pending approvals.
Key Highlights
Acquisition valued at approximately ₹16,700 Million
Target Companies' annual revenues of approximately ₹11,791 Million
Acquisition of 100% stake in Antolin Group’s Indian Operations
Transaction expected to be completed by January 2, 2026
💼 Action for Investors
This acquisition diversifies SPRL's portfolio into automotive interiors, potentially enhancing long-term growth. Investors should monitor the integration process and synergies realized from this acquisition.
JKIPL welcomes RBI's growth policy, rupee at ₹90/USD boosts exports
Jinkushal Industries Limited (JKIPL) welcomes the RBI's decision to reduce the policy repo rate by 25 basis points to 5.25%. The company highlights the rupee's movement from ₹83 per US dollar in December 2024 to ₹90 per US dollar in December 2025, which significantly improves export competitiveness. JKIPL notes that a USD 100,000 export invoice now yields nearly ₹90 lakh compared to ₹83 lakh in December 2024, resulting in a gain of roughly ₹7 lakh per invoice. This strengthens margins and enables reinvestment in technology and global reach.
Key Highlights
RBI reduced the policy repo rate by 25 basis points to 5.25%.
Rupee moved from approximately ₹83 per US dollar to around ₹90 per US dollar.
USD 100,000 export invoice yielded about ₹83 lakh in December 2024.
USD 100,000 export invoice realizes nearly ₹90 lakh in December 2025.
Gain of roughly ₹7 lakh per invoice due to currency movement.
💼 Action for Investors
Investors should monitor JKIPL's export performance and margin improvements due to the favorable exchange rate. Keep an eye on how the company reinvests the increased revenue from exports.
Capillary Technologies to Ratify ESOP 2021 Scheme for 72.91 Lakh Options
Capillary Technologies has issued a postal ballot notice to ratify its existing 'Capillary Employees Stock Option Scheme-2021' (ESOP 2021). This ratification is a regulatory requirement under SEBI (SBEB & SE) Regulations following the company's listing on the stock exchanges. The scheme involves up to 72,91,000 options, each convertible into one equity share of face value ₹2. Shareholders can participate in the e-voting process from December 6, 2025, to January 4, 2026.
Key Highlights
Ratification of ESOP 2021 involving a total of 72,91,000 employee stock options.
Each option is exercisable into one equity share of face value ₹2 each.
E-voting period is scheduled from December 6, 2025, to January 4, 2026.
The scheme was previously approved by members on May 30, 2025, prior to the company's listing.
The resolution is proposed as a Special Resolution to comply with SEBI post-listing mandates.
💼 Action for Investors
Investors should view this as a routine compliance matter for a newly listed company to maintain its talent retention programs. Note the potential equity dilution of approximately 7.29 million shares as options are exercised over time.
Dabur India Receives BSE Observation Letter for Sesa Care Amalgamation
Dabur India Limited received an observation letter with 'no adverse observations' from BSE Limited on December 04, 2025, regarding the Scheme of Amalgamation of Sesa Care Private Limited with Dabur India. This scheme is subject to statutory and regulatory approvals, including those from shareholders and creditors. The observation letter is available on the company's website, www.dabur.com. This amalgamation is under Sections 230 to 232 of the Companies Act, 2013.
Key Highlights
BSE issued 'no adverse observations' on December 04, 2025, for the amalgamation scheme.
The scheme involves the amalgamation of Sesa Care Private Limited with Dabur India Limited.
The amalgamation is governed by Sections 230 to 232 of the Companies Act, 2013.
The BSE observation letter is available on Dabur's website: www.dabur.com
💼 Action for Investors
Investors should monitor further announcements regarding the progress of the amalgamation, including shareholder and regulatory approvals. Review the observation letter on Dabur's website for more details.
Senores Pharma Receives Philippine FDA Approval for 10 Products
Senores Pharmaceuticals has received marketing authorizations from the Philippine FDA for 10 products across Cardiovascular, CNS, and Pain management therapies. The market size of these drugs in the Philippines is valued at US $23 million, representing a significant growth opportunity. This approval allows Senores to expand its footprint in Southeast Asia and provide affordable healthcare options. The company has 32 own ANDA and 32 CMO/CDMO commercial products permitted for distribution in the USA.
Key Highlights
Received Philippine FDA approval for 10 products
Market size of approved drugs in the Philippines is US $23 million
Company has 32 own ANDA products for distribution in the USA
Company has 32 CMO/CDMO commercial products for distribution in the USA
Company caters to more than 40 countries
💼 Action for Investors
Investors should monitor Senores Pharmaceuticals' progress in the Philippines and its impact on revenue growth. Keep an eye on further regulatory approvals and expansion into other markets.
DHRUV Receives ₹5.25 Crore Consultancy Project from NHAI
Dhruv Consultancy Services Limited has been appointed by the National Highway Authority of India (NHAI) for consultancy services. The project involves preparation of DPR/Feasibility Report for multiple highway sections in Kerala. The total consideration for this project is ₹5,25,17,190 (excluding GST). The project duration is 9 months, and this new project should positively impact Dhruv's revenue stream.
Key Highlights
Project awarded by NHAI
Project value: ₹5,25,17,190 (excluding GST)
Project duration: 9 months
Involves development of multiple NH sections
💼 Action for Investors
Investors should monitor Dhruv's progress on this project and its impact on the company's financials in the coming quarters. This project win signals continued growth and expansion for the company.
India Glycols: CGST Appeal Allowed, ₹1,92,12,510 Demand Dropped
India Glycols Limited received a favorable order from the Commissioner, CGST (Appeals), Noida, setting aside the earlier demand order issued by the Joint Commissioner, CGST, Noida. The original order had disallowed Transitional Input Tax Credit (ITC) and demanded ₹1,92,12,510 along with equivalent penalty and applicable interest. With the appeal being allowed, the demand for tax, penalty, and interest now stands dropped, resulting in no financial impact on the company.
Key Highlights
Demand of ₹1,92,12,510 for disallowed Transitional Input Tax Credit (ITC) dropped.
Order dated 28th January 2025 passed by Joint Commissioner, CGST, Noida, was set aside.
Appeal allowed by Commissioner, CGST (Appeals), Noida on 26th November 2025.
Order received by the company on 4th December, 2025.
💼 Action for Investors
This is a positive development as it removes a contingent liability of ₹1,92,12,510. Investors can view this as a reduction in potential financial risk for India Glycols.
Cummins India Seeks Approval for ₹290 Cr Additional Related Party Transactions
Cummins India Limited has issued a postal ballot notice to seek shareholder approval for additional material related party transactions (RPTs) for FY 2025-26. The company is proposing an additional limit of ₹40 crores for transactions with Cummins Inc., USA, and ₹250 crores for transactions with Cummins Limited, UK. These transactions primarily involve the purchase and sale of engines, gensets, and spare parts. These limits are over and above the approvals previously granted by shareholders during the Annual General Meeting in August 2025.
Key Highlights
Proposed additional RPT limit of ₹40 crores with Cummins Inc., USA for engine and parts purchases.
Proposed additional RPT limit of ₹250 crores with Cummins Limited, UK for both purchase and sale of engines and spares.
Transactions are intended for the Financial Year 2025-26 and are conducted at arm's length.
E-voting period for shareholders is scheduled from December 7, 2025, to January 5, 2026.
The approvals are incremental to the existing limits sanctioned at the AGM held on August 8, 2025.
💼 Action for Investors
Investors should note these transactions as part of the company's integrated global supply chain operations; no immediate action is required unless there are concerns regarding the arm's length pricing.
GANESHHOU Approves Scheme of Arrangement with Gatil Properties
Ganesh Housing Limited's board approved a Scheme of Arrangement with Gatil Properties Private Limited, a wholly-owned subsidiary. The appointed date for the scheme is April 1, 2025. The scheme aims to simplify the corporate structure and consolidate business activities, potentially leading to economies of scale. As part of the scheme, the company will write off the debit balance in Capital Reserve amounting to ₹498.56 Cr against the Securities Premium Account.
Key Highlights
Scheme of Arrangement approved between Ganesh Housing Limited and Gatil Properties Private Limited.
Appointed Date of the Scheme is April 1, 2025.
Gatil Properties Private Limited's turnover (standalone) for the year ended March 31, 2025 was ₹26488.96 lakhs.
Ganesh Housing Limited's turnover (standalone) for the year ended March 31, 2025 was ₹67629.26 lakhs.
The Transferee Company shall write off the debit balance of Capital Reserve amounting to ₹498.56 Cr against the Securities Premium Account.
💼 Action for Investors
Investors should monitor the progress of the scheme and its impact on Ganesh Housing's financials. Review the scheme document on the company website for detailed information.
Ravindra Energy Approves 8 New Solar Subsidiaries and Revisions to Loan & RPT Limits
Ravindra Energy's board has approved the incorporation of 8 new wholly-owned subsidiaries focused on solar and renewable energy projects between November 29 and December 4, 2025. The company is seeking shareholder approval via postal ballot to revise limits for loans, guarantees, and securities provided to subsidiaries and associates under Section 185. Additionally, the board recommended revising material related party transaction limits with Energy In Motion Limited (EIM). These structural and financial changes indicate a significant scaling effort in the renewable energy sector.
Key Highlights
Incorporation of 8 new solar project subsidiaries including REL MSKVY and Ravindra Energy KNSP series.
Proposed revision of financial limits for loans, guarantees, and securities for subsidiaries and associates.
Revision of material related party transaction (RPT) limits with Energy In Motion Limited (EIM).
Appointment of Mr. Apurva Chandra as Independent Director for a 5-year term effective November 5, 2025.
Reorganization of Audit and Nomination & Remuneration Committees following new director inductions.
💼 Action for Investors
Investors should monitor the upcoming postal ballot for specific details on the new loan and RPT limits. The aggressive creation of new SPVs suggests a strong project pipeline in the solar energy space.
IPCALAB: US FDA inspects Tarapur API facility, issues Form 483 with 3 observations
The US FDA conducted an inspection of IPCA Laboratories' Active Pharmaceutical Ingredients (APIs) manufacturing facility in Tarapur (Palghar-Maharashtra) from December 1st to December 5th, 2025. Following the inspection, the US FDA issued a Form 483, which included 3 observations. IPCA Laboratories plans to submit a comprehensive response to the US FDA within the stipulated timeframe. The company is committed to resolving the issues and maintaining high standards of quality and compliance.
Key Highlights
US FDA inspected IPCA's API facility in Tarapur from December 1st to 5th, 2025
US FDA issued a Form 483 with 3 observations
IPCA will respond to US FDA within the stipulated time
💼 Action for Investors
Investors should monitor IPCA's response to the US FDA's observations and any subsequent updates regarding the facility's compliance status. Any negative resolution could impact future revenue.
Veedol Corp: Standalone Revenue from Operations at ₹351.51 cr for Sep 2025
Veedol Corporation Limited announced its standalone financial results for the period ended September 30, 2025. The company's Revenue from Operations stood at ₹351.51 crores. Total Income was reported as ₹378.70 crores. The Profit for the Period reached ₹26.39 crores, resulting in Basic Earnings per Equity Share of ₹15.52.
Key Highlights
Standalone Revenue from Operations (Including Other Operating Revenue) for the quarter ended September 30, 2025 was ₹351.51 crores.
Standalone Total Income for the quarter ended September 30, 2025 was ₹378.70 crores.
Standalone Profit for the Period for the quarter ended September 30, 2025 was ₹26.39 crores.
Basic Earnings per Equity Share (of Rs. 2/- each) for the quarter ended September 30, 2025 was ₹15.52.
💼 Action for Investors
Investors should review the complete financial results and compare them against previous periods and competitor performance to understand the company's financial health and growth trajectory. Monitor the insurance claim related to the fire incident at Bhiwandi, Maharashtra, which impacted inventory worth ₹6.56 crores.
PNC Announces Final Season of 'Four More Shots Please!' Premiere on Prime Video Dec 19
Pritish Nandy Communications (PNC) has scheduled the global premiere of the fourth and final season of its flagship series, 'Four More Shots Please!', for December 19, 2025. The International Emmy-nominated series will be available on Prime Video across more than 240 countries and territories. This launch marks the culmination of a decade-long franchise, which has been a significant content asset for the company. The successful delivery of this high-profile project is expected to reflect in the company's upcoming revenue cycles.
Key Highlights
Final season of the International Emmy-nominated series to premiere on December 19, 2025
Global distribution secured via Prime Video in 240+ countries and territories
Project marks the conclusion of a decade-long franchise produced by PNC
Series created by Rangita and Ishita Pritish Nandy, featuring a high-profile ensemble cast
💼 Action for Investors
Investors should track the company's Q3 and Q4 FY26 earnings to gauge the financial realization from this major content delivery. The successful execution of global streaming projects strengthens PNC's position for future high-value commissions.
FCL acquires US Specialty Oilfield Chemicals Group via subsidiary
Fineotex Chemical Limited, through its subsidiary Fineotex Biotex Healthguard FZE, has acquired equity interests in FrackMex Equipment, CrudeChem Technology, Oil Pro Advantage, and Lonestar Technoboost. The acquisition aims to expand Fineotex's business in the Specialty Chemical Sector. CrudeChem Technology's turnover for FY 2024-25 was USD 5,30,21,551. Fineotex Biotex Healthguard FZE acquires 53.33% stake in each of the entities. The cost of acquisition for CrudeChem Technology is upto USD 1,10,07,360.
Key Highlights
CrudeChem Technology LLC Turnover FY 2024-25: USD 5,30,21,551
FrackMex Equipment and Services LLC Turnover FY 2024-25: USD 32,45,478
Lonestar Technoboost LLC Turnover FY 2024-25: USD 1,11,44,958
Oil Pro Advantage INC Turnover FY 2024-25: USD 4,46,793
Fineotex Biotex Healthguard FZE acquires 53.33% stake in each company
💼 Action for Investors
This acquisition signals Fineotex's strategic expansion into the US oilfield chemicals market; investors should monitor the integration and performance of these acquired entities for future growth contributions.
FCL Acquires US Specialty Oilfield Chemicals Group via Subsidiary
Fineotex Chemical Limited (FCL) has announced a strategic acquisition of a leading U.S. Specialty Oilfield Chemicals Group through its wholly-owned subsidiary, Fineotex Biotex Healthguard FZE. The acquisition includes equity interests in FrackMex Equipment, CrudeChem Technology, Oil Pro Advantage INC, and Lonestar Technoboost LLC. CrudeChem Technology LLC's turnover was USD 53,021,551 in FY 2024-25. The company aims to build a $200 million oil field chemical business in the coming years.
Key Highlights
Fineotex Biotex Healthguard FZE acquires 53.33% stake in each of the four US companies.
CrudeChem Technology LLC turnover for FY 2024-25 was USD 53,021,551.
Cost of Acquisition for CrudeChem Technology LLC is upto USD 11,007,360.
FrackMex Equipment and Services LLC turnover for FY 2024-25 was USD 3,245,478.
The North American addressable market industry size represents $11.5 billion in 2025.
💼 Action for Investors
This acquisition signals Fineotex's expansion into the US market and its commitment to the specialty chemicals sector; investors should monitor the integration and performance of the acquired entities for future growth contributions.
Moneyboxx Finance Increases Authorized Share Capital to ₹100 Crore from ₹40 Crore
Moneyboxx Finance has received shareholder approval to significantly expand its authorized share capital from ₹40 crore to ₹100 crore. This 150% increase allows the company to issue up to 10 crore equity shares, up from the previous limit of 4 crore shares. The resolution was passed via postal ballot on December 4, 2025, with the scrutinizer's report finalized on December 5, 2025. This structural change is a clear precursor to future equity fundraising or capital expansion to support the company's growth trajectory.
Key Highlights
Authorized share capital increased from ₹40,00,00,000 to ₹100,00,00,000
Total equity share capacity expanded from 4 crore shares to 10 crore shares at ₹10 face value
Shareholder approval obtained via Postal Ballot on December 4, 2025
Consequential amendment made to Clause V of the Memorandum of Association (MOA)
Move provides the company with significant headroom for future equity-based fundraising
💼 Action for Investors
Investors should monitor the company for upcoming announcements regarding specific fundraising plans or equity dilution, as this move prepares the ground for fresh capital infusion.